Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Cipla
Dow
Cantor Fitzgerald
Teva
McKinsey
Medtronic
Accenture
AstraZeneca

Generated: October 21, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,946,235

« Back to Dashboard

Which drugs does patent 8,946,235 protect, and when does it expire?


Patent 8,946,235 protects TAGRISSO and is included in one NDA.

This patent has seventy-one patent family members in thirty-four countries.

Summary for Patent: 8,946,235

Title:2-(2,4,5-substituted-anilino) pyrimidine compounds
Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using such compounds and salts thereof.
Inventor(s): Butterworth; Sam (Cheshire, GB), Finlay; Maurice Raymond Verschoyle (Cheshire, GB), Ward; Richard Andrew (Cheshire, GB), Redfearn; Heather Marie (Cheshire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:13/557,871
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-001Nov 13, 2015RXYesNo► Subscribe► SubscribeYY TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTORE RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
Astrazeneca Pharms
TAGRISSO
osimertinib mesylate
TABLET;ORAL208065-002Nov 13, 2015RXYesYes► Subscribe► SubscribeYY TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTORE RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,946,235

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,732,0582-(2,4,5-substituted-anilino)pyrimidine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,946,235

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina087336► Subscribe
Australia2012288626► Subscribe
Brazil112014001768► Subscribe
Canada2843109► Subscribe
Canada2881987► Subscribe
Canada2881991► Subscribe
Canada2881993► Subscribe
Canada2882018► Subscribe
China103702990► Subscribe
China104109151► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Accenture
Medtronic
Fuji
Dow
Colorcon
Cerilliant
Federal Trade Commission
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot